Copenhagen, DENMARK - October 29, 2001 - Genmab A/S (CSE: GEN and Neuer Markt: GE9D) announced today that Jan van de Winkel, Ph.D., Chief Scientific Officer, will present an initial analysis of the HuMax-CD4 Phase II dose finding psoriasis study at the American College of Rheumatology Conference in San Francisco. These results will be based on analysis of 79 of the 85 patients in the study. Dr. Jan van de Winkel will discuss this information on Monday, November 12, 2001 in a talk entitled "Novel Antibody Therapeutic Approaches for Inflammation."

"This Phase II study began in January of this year and has been completed rapidly. Clinical progress is the key to success in biotech, and the Genmab team continues to be highly effective at delivering it," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.